In the evening of September 21, 2019, the Award Ceremony of ‘Dushu Lake Prize’ Selection of China Pharmaceutical Innovation Brand (herein after referred to as the Selection Activities), co-hosted by China Pharmaceutical Innovation and Research Development Association (PhIRDA) and Suzhou Industrial Park (SIP) was successfully hosted in the Suzhou Broadcasting System (SBS) Studio Hall in Suzhou, China, and broadcast live on the internet.

The Award Ceremony was attended by Wu Qingwen, Member of the Standing Committee of CPC Suzhou Committee, Secretary of SIP Working Committee, and Song Ruilin, Chairman of PhIRDA, as representative of the host. Chen Kaixian, Deputy Chief Engineer of National Science and Technology Major Project for Major New Drug Research and Development, Researcher of Shanghai Institute of Materia Medica of Chinese Academy of Sciences, Academician of Chinese Academy of Sciences, Jiang Hualiang, Academician of Chinese Academy of Sciences, professor of Shanghai Institute of Materia Medica, Yue Jianmin, Academician of Shanghai Institute of Materia Medica of Chinese Academy of Sciences, Ding Jian, Director of the Academic Committee of Shanghai Institute of Materia Medica, Dean of School of Pharmacy of University of the Chinese Academy of Sciences (UCAS), Chinese Academy of Sciences, Academician of the Chinese Academy of Engineering, Zhao Kai, Research Fellow of National Vaccine and Serum Institute, Academician of Chinese Academy of Engineering, Ge Junbo, Dean of Institutes of Biomedical Sciences Fudan University and Academician of Chinese Academy of Sciences, as well as other 22 experts from Review Expert Committee of Selection Activities. Li Linkang, Executive Chair of China Alliance for Rare Diseases, Vice President of Chinese Hospital Association (CHA), and Lo Yuk Lam, Chairman of HK Bio-Med Innotech Association (HKBMIA) announced and presented awards on the Award Ceremony.

Over 400 guests and participants attended the Award Ceremony including representatives from nominated innovative projects or enterprises, prestigious experts, scholars, entrepreneurs and so on.

The Final Review Meeting was held only 3 hours before the start of the Award Ceremony. The votes were cast by review experts in a secret ballot and counted by the staff from Selection Activities Office on the spot. The final result would not be released to the public until the Award Ceremony.

As the host representative, Song Ruilin, Chairman of PhIRDA, introduced the background and state quo of Selection Activities. For a more authoritative and fairer selection, all standards of organization and management had been improved and perfected this year. Moreover, the joining of more professionals and new-set innovation awards featured in the Selection Activities and brought a distinctive edge to the event.

I. Gearing to International Selections and Standards

1. More Authoritative Experts and Wider Review Range

The Review Committee of Selection Activities is chair by Academician Sang Guowei and Academician Chen Kaixian, gathering many authoritative clinical and pharmaceutical experts in the field of pharmaceutical innovation R&D. In this year, another 8 leading experts from the fields of neurobiology, biological signal transduction, basic research of liver cancer, clinical metabolism and hematology of tumor joined the Review Committee, which broadened the review range and subdivision. The number of Review Committee has reached 57 experts, including 17 academicians.

2. More Reasonable Review Standard to Make More Fair, Open and Transparent Selection

Experts above vice-chairman from Chinese Hospital Association (CHA) and China Alliance for Rare Diseases (CARD) were empowered to recommend projects. Any experts who were involved in revising the selection standards and stipulating the category of projects recommended, shall not participate in the review of relevant project. Any experts who were nominated in pharmaceutical innovation figures shall not participate in the evaluation of the year.

For a more transparent review and selection, the list of expert committees, all the range of experts with the right to recommend, selection standard and selection were published online, moreover, a computer system scoring was adopted for project review in the Selection Activities.

II. Optimized Award Categories

The award for ‘Most Valuable Design of Drug Clinical Protocol’ was newly set to improve domestic clinical research design and management. The original award for ‘Innovative Pediatric Drug/Orphan Drug with Most Clinical Value’ was divided into two independent awards separately according to national policy for encouraging R&D for medicines for rare diseases and children.

III. Always Public Welfare-oriented Principle

Adhering to the public welfare-oriented principle, no fees will be charged in the Selection Activities for the event’s fairness and justice.

Innovative Figures will win the award of RMB 100,000 yuan/person for nominees, and RMB 500,000 yuan/person for final winner, and RMB 800,000 yuan/person for Lifetime Achievement Award winner.

Addressed by Song Ruilin, Chairman of PhIRDA

Wu Qingwen, Member of the Standing Committee of CPC Suzhou Committee, Secretary of SIP Working Committee, highly praised the influence of 2019 Activities Selection upon the industry, and expressed his hope for an event with higher standards and authority.

Addressed by Wu Qingwen, Member of the Standing Committee of CPC Suzhou Committee, Secretary of SIP Working Committee

The result of award winners were announced in the exciting ceremony. 

Announcing and Presenting Awards

I. Lifetime Achievement Award of Pharmaceutical Innovation: Sun Yan, Director of National GCP Center for Anticancer Agents, NCC, CAMS, Academician of Chinese Academy of Engineering

The Award was announced by Wu Qingwen, Member of the Standing Committee of CPC Suzhou Committee, Secretary of SIP Working Committee, and presented by Chen Kaixian, Professor, Academician of CAS, Shanghai Institute of Materia Medica, Chinese Academy of Sciences. As Academician Sun’s student, Shi Yuankai, Deputy-director of the National Cancer Center (CNCC) and Vice President of Cancer Hospital, Chinese Academy of Medical Sciences, presented the bouquet.

Winner of Lifetime Achievement Award of Pharmaceutical Innovation: Academician Sun Yan (the second from left)
Award announcers and presenters: Academician Chen Kaixian (the second from right); Secretary Wu Qingwen (the first from left); Academician Sun’s student President Shi Yuankai (the first from right)

II. Most Innovative Figure of Drug R&D Award (International Areas): Dr. Liu Yongjun, Global Head of Research, Sanofi

The award was presented by Academician Ding Jian, Director of the Academic Committee of Shanghai Institute of Materia Medica, Dean of School of Pharmacy of University of the Chinese Academy of Sciences (UCAS), Chinese Academy of Sciences, Academician of the Chinese Academy of Engineering, and announced by Dr. Song Wenru, expert of Review Committee of Selection Activities and Co-founder of Kira Pharmaceuticals.

Winner of Most Innovative Figure of Drug R&D Award (International Areas): Dr. Liu Yongjun (in the middle)
Award announcers and presenters:
Academician Ding Jian (the right);
Dr. Song Wenru (the left)

III. Award for Most Innovative Figure of Drug R&D

1. Winner of Most Innovative Figure of Drug R&D Award: Dr. Yu Dechao Chairman of the Board & CEO, Innovent Biologics

2. Nominee for Most Innovative Figure of Drug R&D Award: Dr. Wang Zhiwei, Senior Vice President of BeiGene

The Awards for Most Innovative Figure of Drug R&D winner and nominee was respectively presented by Jiang Hualiang, Academician of Chinese Academy of Sciences, professor of Shanghai Institute of Materia Medica, and Lo Yuk Lam, Chairman of HK Bio-Med Innotech Association (HKBMIA), and announced by Dr. He Ruyi, Chief Scientist at SDIC.

Winner of Most Innovative Figure of Drug R&D Award: Dr.Yu Dechao (in the middle)
Award announcers and presenters: Academician Jiang Hualiang (the right); Dr. He Ruyi (the left)

Nominee for Most Innovative Figure of Drug R&D Award: Dr. Wang Zhiwei
Award announcers and presenters: Chairman Lo Yuk Lam and Dr. He Ruyi

IV. Award for Most Innovative Figure of Clinical R&D 

Two winners of Most Innovative Figure of Clinical R&D Award:

Professor Hou Jian, Director of the Department of Hematology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, and Professor Zhang Li, Department of Respiratory Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences.

The awards were presented by CAS Academician Yue Jianmin, professor of Shanghai Institute of Materia Medica, and professor Wu Xiaoming, former President of China Pharmaceutical University, and announced by Wu Chunfu, professor of Shenyang Pharmaceutical University and Li Wenbin, Director of the Department of Neurooncology, Beijing Tiantan Hospital, Capital Medical University

Winners of Most Innovative Figure of Clinical R&D Award: Prof. Hou Jian (the third in the left) and Prof. Zhang Li (the third in the right)

Award announcers and presenters: Academician Yue Jianmin (the second in the right); Prof. Wu Xiaoming (the first in the left); Prof. Wu Chunfu (the first in the right); Dr. Li Wenbin (the second in the left)

V. Award for Clinical Trial Protocol Design: ‘Gemcitabine combined with Cisplatin induction chemotherapy for nasopharyngeal carcinoma’ Clinical Trial Protocol

The award was presented by CSA Academician Ge Junbo, Dean of Institutes of Biomedical Sciences Fudan University, and announced by Zhang Shucai, Director of Oncology department of Beijing Chest Hospital, Capital Medical Hospital.

Winner of Clinical Trial Protocol Design Award:
Prof. Ma Jun, Sun Yat-Sen University Cancer Center (in the middle)
Award announcers and presenters:
Academician Ge Junbo (the right); Dr. Zhang Shucai (the left)

VI. Award for Innovative Drug with Most Clinical Value

1. Winner of Innovative Drug with Most Clinical Value Award: Roxadustat Capsule from Fibrogen (China) Medical Technology Development Co., Ltd.

2. Nominee for Innovative Drug with Most Clinical Value Award:

Sintilimab injection (Tyvyt^®) from Innovent Biologics / Toripalimab Injection (JS001/Tuoyi®) from Junshi Biosciences.

The award was presented by Xuan Jianwei, Director of Health Economics Research Institute, School of Pharmaceutical Sciences, Sun Yat-Sen University and expert of Review Committee of the Selection Activities, Linghu Enqiang, endoscopist and Director at the Department of Gastroenterology and Hepatology, General Hospital of the People's Liberation Army (PLAGH). The award announcers were Professor Shen Xinliang, Deputy Chairman, Director of the Genetic Engineering Drugs at the Chinese Academy of Committee of the Vaccines, China Medicinal Biotech Association (CMBA), and Zhong Wu, Director of National Engineering Research Center for the Emergency Drug, Academy of Military Medical Sciences.

Winner Representative of Innovative Drug with Most Clinical Value Award:
Ms. Zhongli Yunhua, Managing Director, FibroGen (China) (the second from the right)
Award announcers and presenters:
Dr. Xuan Jianwei (the second from the left);
Prof. Shen Xinliang (the first from the right);
Dr. Zhong Wu (the first from the left) 

Nominee for Innovative Drug with Most Clinical Value Award:
Mr. Zhou Qinwei, COO of Innovent Biologics (Suzhou) Co. Ltd. (the second from the left);
Mr. Li Ning, CEO of Junshi Biosciences Co, Ltd (in the middle)
Award announcers and presenters:
Dr. Linghu Enqiang (the second from the right);
Prof. Shen Xinliang (the first from the right);
Dr. Zhong Wu (the first from the left)

VII. Award for Innovative Pediatric Drug

1. Award for Innovative Pediatric Drug with Most Clinical Value

Inactivated Poliomyelitis Vaccine Made From SabinStrains(Vero cell) and Poliomyelitis (Live) Vaccine Type I Type III (Human Diploid Cell), Oral from China National Biotech Corporation

2. Nominee for Innovative Pediatric Drug with Most Clinical Value Award: Kewei (Oseltamivir Phosphate Granule) from Yichang Changjiang Pharmaceutical Company Limited

Awards for winner and nominee was respectively presented by CAE Academician Zhao Kai, researcher of National Vaccine & Serum Institute, and Professor Wang Junzhi, chief expert for Biological product testing in National Institutes for Food and Drug Control, and announced by Ren Jin, Director of Centre for Drug Safety Evaluation and Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences.

Winner of Innovative Pediatric Drug with Most Clinical Value Award:
Mr. Yang Xiaoming, Chairman of China National Biotech Corporation (in the middle)
Award announcers and presenters:
Academician Zhao Kai (the right)
Dr. Ren Jin (the left)

Nominee for Innovative Pediatric Drug with Most Clinical Value Award:
Mr. Tang Xinfa, Chairman of Yichang Changjiang Pharmaceutical Company Limited (in the middle)
Award announcers and presenters:
Prof. Wang Junzhi (the right)
Dr. Ren Jin (the left)

Winners, Award Announcers and Presenters, Host Representatives and VIP Guests

In the award ceremony, over 400 participants and audiences witnessed the final award winners of 2019 ‘Dushu Lake Prize’ Selection Activities of China Pharmaceutical Innovation Brand jointly, which caught the eyes of the entire pharmaceutical industry, and they were deeply impressed by the flourishing growth of the innovative pharmaceutical industry in China.

Increasing leading projects and figures are actively participating the Selection Activities, and growing authoritative experts are joining in the Review Committee, which fully demonstrates the Selection Activities’ core idea - To promote the scientific evaluation system by objective and neutral criteria, and to build fair evaluation by mechanism of openness and transparency, supervision and avoidance. The Selection Activities is gaining wider recognition within the industry and with greater influence and authority in China and Asia-Pacific region. The event also attaches great importance to the development of China's pharmaceutical innovation and establishment of sound brands for China's pharmaceutical innovation.

Awards Ceremony and VIP Guests

Nominee for all Awards Lists: